Merck (MRK) Total Debt (2009 - 2026)
Merck (MRK) posted quarterly Total Debt of $49.1 billion for Q1 2026, up 40.96% year-over-year from $34.8 billion in Q1 2025, and little changed quarter-over-quarter from $49.3 billion in Q4 2025.
Merck (MRK) Total Debt (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Total Debt for 18 consecutive years, with $49.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 40.96% year-over-year to $49.1 billion; the TTM figure through Mar 2026 stood at $49.1 billion (up 40.96% YoY), while the FY2025 annual figure was $49.3 billion, up 32.95% from the prior year.
- Total Debt steadied at $49.1 billion in Q1 2026 per MRK's latest filing, from $49.3 billion in the prior quarter.
- Across five years, Total Debt topped out at $49.3 billion in Q4 2025 and bottomed at $30.4 billion in Q3 2022.
- Historically, Total Debt has averaged $36.4 billion across 5 years, with a median of $35.1 billion in 2023.
- Annual changes were most pronounced in 2022 — Total Debt retreated 7.28% — and 2026, when it jumped 40.96%.
- Merck's Total Debt stood at $30.7 billion in 2022, then grew by 14.22% to $35.1 billion in 2023, then rose by 5.87% to $37.1 billion in 2024, then jumped by 32.95% to $49.3 billion in 2025, then fell by 0.45% to $49.1 billion in 2026.
- Business Quant data shows MRK's Total Debt at $49.1 billion in Q1 2026, $49.3 billion in Q4 2025, and $41.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.91 Bn |
| Mar 31, 2026 | 49.12 Bn |
| Dec 31, 2025 | 49.34 Bn |
| Sep 30, 2025 | 41.37 Bn |
| Jun 30, 2025 | 35.40 Bn |
| Mar 31, 2025 | 34.84 Bn |
| Dec 31, 2024 | 37.11 Bn |
| Sep 30, 2024 | 38.13 Bn |
| Jun 30, 2024 | 37.79 Bn |
| Mar 31, 2024 | 34.22 Bn |
| Dec 31, 2023 | 35.06 Bn |
| Sep 30, 2023 | 34.86 Bn |
| Jun 30, 2023 | 36.91 Bn |
| Mar 31, 2023 | 30.75 Bn |
| Dec 31, 2022 | 30.69 Bn |
| Sep 30, 2022 | 30.42 Bn |
| Jun 30, 2022 | 31.66 Bn |
| Mar 31, 2022 | 31.79 Bn |
| Dec 31, 2021 | 33.10 Bn |
| Sep 30, 2021 | 26.44 Bn |